Evolent Health sits at an unusual intersection in healthcare: it is simultaneously a technology and services vendor to health plans, an operator of specialty benefit management programs, and an increasingly sophisticated player in AI-driven claims processing — all of which place it in a position that affects provider revenue cycles in ways most billing directors have not fully mapped. With $2.55 billion in revenue reported for FY2024, up from $1.96 billion in 2023, and an additional $900 million in new Performance Suite revenue expected in 2026, Evolent is not a peripheral vendor — it is a structurally significant force reshaping how specialty care gets authorized, paid, and managed across a large swath of commercial and government-sponsored lives.
Executive Summary
- Evolent reported $2.55B in FY2024 revenue, a 30% increase over FY2023's $1.96B, with revenues growing at an average rate of 23.5% per year — driven by health plan outsourcing of specialty benefit management and prior authorization operations.
- Evolent's acquisition of Machinify brings AI-native claims processing capability in-house, signaling a direct expansion into the automation layer of health plan adjudication that will affect provider clean-claim rates on Evolent-managed payer contracts.
- Specialty providers — particularly oncology and cardiology practices — submitting claims through Evolent-managed payers face a dual dynamic: Evolent controls both the prior auth decision layer (via New Century Health) and, increasingly, the claims processing infrastructure, creating compounding denial risk that standard RCM workflows are not built to catch.
Understanding Evolent requires recognizing that it was not built as a provider-side RCM company. It was built to help health plans and provider organizations manage financial risk in value-based arrangements — starting from its 2011 founding by The Advisory Board Company and UPMC Health Plan, which contributed operational infrastructure and institutional knowledge of integrated payer-provider models. That origin shapes everything about how Evolent operates today, including the specific ways its growth creates friction — and occasionally leverage — for specialty practices billing into its managed programs.
The Landscape: Evolent In 2026
The value-based care services market has matured considerably since Evolent's early years, when it was essentially helping health systems stand up the infrastructure to accept capitation and shared savings contracts. Today, the company has pivoted heavily toward health plan operational outsourcing — specifically, taking over the specialty benefit management functions that health plans historically ran in-house or outsourced to siloed utilization management vendors. This includes prior authorization for high-cost specialties, specialty network design and management, clinical program development for oncology and cardiology, and increasingly, the administrative infrastructure that sits between a plan's core claims system and the clinical policies governing what gets paid.
The regulatory environment has accelerated this trend. CMS's prior authorization final rule (CMS-0057-F, published January 2024) took effect for Medicare Advantage, Medicaid managed care, and CHIP plans on January 1, 2026, and for impacted payers on the federal exchange beginning January 1, 2027. The rule requires payers to respond to urgent PA requests within 72 hours and standard requests within seven calendar days, to provide specific clinical reasons for denials, and to implement HL7 FHIR-based PA APIs. Health plans that lack the internal infrastructure to operationalize these requirements at scale have increasingly turned to outsourced specialty benefit managers like Evolent's New Century Health subsidiary to handle these workflows. For providers, that means the entity making the prior auth decision on an oncology drug or an interventional cardiology procedure may be Evolent — operating under the branding and contractual umbrella of the health plan, but running its own clinical criteria, its own physician reviewer networks, and its own appeals processes.
CMS's final prior auth rule (CMS-0057-F) requires MA and Medicaid managed care plans to issue standard auth decisions within 7 calendar days and urgent decisions within 72 hours, with mandatory specific denial rationale and FHIR-based PA API implementation — compliance pressure that is driving health plan outsourcing to specialty benefit managers.
The market Evolent is operating in is substantial. The global healthcare RCM market is projected to reach approximately $240–$290 billion by 2030 depending on methodology and scope of services included — specialty benefit management sits at the highest-complexity, highest-cost end of that market. Evolent's bet is that health plans will continue to outsource specialty cost management rather than build it internally — and the revenue trajectory suggests that bet is paying off.
The Platform: How Evolent Is Structured
Evolent operates across three primary functional areas that RCM professionals need to understand as distinct but increasingly integrated components. The first is the Evolent Performance Suite, which is the health plan operational services offering — a broad outsourcing arrangement in which health plans contract with Evolent to manage clinical and administrative functions including utilization management, specialty care coordination, and population health analytics. Performance Suite contracts are structured on a per-member-per-month basis, with revenue driven by the number of lives under management and the scope of services delegated to Evolent. The $900 million in new Performance Suite revenue expected in 2026 reflects significant new contract wins that will bring new populations under Evolent's operational umbrella.
The second component is New Century Health, Evolent's specialty benefit management subsidiary, which is the operational entity that most directly affects specialty providers. New Century Health manages oncology and cardiology benefit programs on behalf of health plans — which means it operates the clinical pathways, the prior authorization criteria, and the medical review processes for those specialty lines. When an oncology practice submits a PA request for a chemotherapy regimen on a patient covered by a health plan that has delegated its oncology benefit management to New Century Health, the provider is effectively dealing with Evolent's clinical and administrative infrastructure, even if the EOB and the health plan contract are with the named payer. This distinction matters enormously for denial management and appeals — the clinical rationale, the reviewer credentials, and the appeal chain all run through New Century Health's processes, not the plan's standard UM department.
Providers appealing denials on Evolent/New Century Health-managed benefits must route through New Century Health's appeal process, not the standard health plan grievance pathway — a mismatch that causes appeals to age out when providers use the wrong process.
The third component is the Machinify acquisition, which represents Evolent's most strategically significant recent move for RCM professionals to monitor. Machinify built AI-native claims processing technology — specifically, tools designed to automate claims adjudication decisions using machine learning against clinical and administrative rules. Integrating Machinify into Evolent's health plan services stack means that Evolent can now offer health plans not just utilization management outsourcing but automated claims adjudication for specialty claims. This is the layer where clean-claim rates, coding edits, and first-pass resolution rates are determined. Specialty practices that are already seeing prior auth friction from New Century Health will face a compounding dynamic if their claims are also adjudicated through Machinify-powered automation on the back end.
Where It Delivers Value
For health plans, Evolent's value proposition is straightforward and well-documented: it reduces specialty medical cost trends through evidence-based clinical pathways, network optimization, and utilization management, while relieving health plans of the administrative burden of building and maintaining these capabilities internally. The per-member-per-month model aligns Evolent's incentives with cost reduction, and the company's ability to bring pre-built oncology and cardiology pathway programs — rather than requiring health plans to develop clinical criteria from scratch — is a genuine differentiator in the managed care market.
For provider organizations operating within Evolent-managed value-based arrangements — particularly those in the Evolent Care Partners network — the platform offers care management infrastructure, shared savings participation mechanics, and population health analytics that support performance under risk contracts. Health systems that have partnered with Evolent have accessed infrastructure for ACO participation, including attribution methodology, cost benchmarking, and quality measure tracking, that would be capital-intensive to build independently.
If your health system has a shared savings arrangement administered by Evolent, request a monthly attribution reconciliation report — discrepancies in attributed lives directly affect your shared savings denominator and can understate performance.
For specialty practices that are not in a formal Evolent partnership but are billing into Evolent-managed health plan programs, the value equation is less obvious. The structure creates a well-defined clinical pathway framework — if your practice is operating on evidence-based oncology pathways and your treatment selections align with National Comprehensive Cancer Network guidelines as interpreted by New Century Health's pathway program, your prior auth approval rates should be high and your administrative burden lower than it would be with a more discretionary UM process. The operational problem arises when practices are off-pathway, when documentation requirements are unclear, or when the plan's member-facing materials do not accurately describe which services require New Century Health authorization versus standard plan UM.
Competitive Positioning
Evolent competes in a fragmented but consolidating market. The most direct competitive comparison for its health plan services business is Optum Health (a UnitedHealth Group subsidiary), which offers a similarly broad set of outsourced clinical and administrative services to health plans and provider organizations. Optum's scale advantage is significant — it operates across a far larger member base and has deeper integration with the UnitedHealthcare plan — but Evolent's independence from any single payer is a genuine selling point for health plans that are reluctant to outsource core operations to a vendor owned by a direct competitor.
Privia Health and Agilon Health compete with Evolent primarily in the physician enablement and value-based care infrastructure space rather than in health plan operations. Privia focuses on primary care practice transformation and network development, while Agilon targets primary care physicians with a capitation model that takes on global risk. Neither has Evolent's specialty benefit management capability or its health plan operations outsourcing infrastructure, which means the competitive overlap is primarily at the provider partnership level — specifically, in markets where health plans are choosing between supporting an Evolent-managed specialty network versus a Privia or Agilon-anchored primary care network as the structural backbone of their value-based strategy.
Evolent's revenue grew at an average rate of 23.5% per year from 2022 through 2024, outpacing typical mid-tier managed care services competitors and reflecting sustained health plan demand for outsourced specialty management.
The Machinify acquisition sharpens Evolent's differentiation against pure-play utilization management vendors like Carelon (Elevance Health's UM subsidiary) and eviCore Healthcare (now operating within Evernorth, Cigna's health services division). Those competitors offer clinical review services but do not natively integrate AI-based claims adjudication. Evolent's post-Machinify stack allows it to position as an end-to-end specialty management platform — from benefit design and clinical pathway development through prior auth, claims adjudication, and outcomes reporting — which is a more complete value proposition for health plans seeking to consolidate vendors.
The 7 Powers Lens: Evolent Strategic Durability
Applying the 7 Powers framework to Evolent is particularly useful for RCM buyers and specialty practice leaders because it reveals not just whether Evolent is a durable business, but where its structural advantages create compounding leverage over providers — and where its weaknesses create negotiating opportunities. Hamilton Helmer's framework asks which of seven specific mechanisms allows a business to maintain persistent differential returns, and for a vendor that sits between payers and providers, each power has direct operational implications for the practices it touches.
| Power | Strength | Assessment |
|---|---|---|
| Scale Economies | Moderate | Fixed cost of clinical pathway development, AI infrastructure (Machinify), and regulatory compliance amortizes across a growing member base — but not yet at Optum's scale |
| Network Economies | Emerging | Specialty provider network participation in New Century Health programs creates a two-sided network; value increases as more practices adopt pathways, but network effects are not yet self-reinforcing |
| Counter-Positioning | Strong | Payer-owned competitors (Optum, Carelon) cannot credibly offer payer-agnostic outsourcing; Evolent's independence is a structural counter-position health plans pay a premium for |
| Switching Costs | Strong | Health plans that have delegated specialty benefit management to Evolent face multi-year transition complexity to reclaim or re-delegate those functions — clinical criteria, provider contracts, and systems integration all require rebuilding |
| Branding | Weak | New Century Health has specialty recognition in oncology and cardiology UM circles, but Evolent lacks consumer or broad provider brand power |
| Cornered Resource | Moderate | Proprietary clinical pathway libraries for oncology and cardiology, combined with Machinify's AI adjudication models trained on specialty claims data, represent difficult-to-replicate assets |
| Process Power | Moderate | Operational expertise in running delegated specialty UM at scale — including CMS compliance workflows under the MA prior auth rule — is genuine but not yet fully systematized into a defensible process moat |
Counter-Positioning as the Core Moat
Evolent's most durable strategic power is counter-positioning against payer-owned competitors, and it deserves direct analysis for RCM professionals who interact with it as a vendor or a payer-side administrator. Large health plans — Blue Cross affiliates, regional Medicaid managed care organizations, smaller national carriers — are structurally unable to outsource specialty benefit management to Optum or Carelon without handing a direct competitor operational insight into their membership, utilization patterns, and benefit design. Evolent's independence from any single payer removes that conflict. This is why Evolent can sign large Performance Suite contracts with plans that would never consider an Optum engagement for equivalent services, and it is why the $900 million in new 2026 Performance Suite revenue reflects real structural demand, not one-time wins.
The Biggest Strategic Vulnerability
Evolent's most significant vulnerability is concentration risk in both customer type and specialty scope. Its health plan revenue is heavily weighted toward a small number of large plan customers, and its clinical expertise is concentrated in oncology and cardiology — two high-cost specialties that are also the target of significant regulatory scrutiny around prior authorization practices. The CMS prior auth rule (CMS-0057-F), combined with state-level PA reform legislation enacted across more than 20 states through 2025 and 2026 — including laws in Texas, Georgia, and Illinois imposing gold-carding requirements and mandatory PA response timelines — creates a regulatory environment in which the utilization management practices that generate Evolent's value for health plans are under sustained challenge. If PA requirements are further restricted — either through federal rulemaking or through state legislation — the volume of specialty authorizations that Evolent manages could compress, directly affecting its per-member-per-month value delivery and contract renewal leverage.
The Switching Cost Reality for Buyers
For health plan executives evaluating Evolent Performance Suite contracts, the switching cost structure deserves explicit attention during initial contract negotiation — because once the transition is complete, recapturing those functions is genuinely expensive. Health plans that delegate oncology benefit management to New Century Health must rebuild provider contract relationships, clinical criteria sets, physician reviewer networks, and appeals infrastructure to reclaim that function. That rebuild typically spans 18 to 24 months and carries significant regulatory risk during the transition period, particularly under CMS's MA prior auth timelines mandated by CMS-0057-F. For specialty practices, this means that Evolent-managed programs are likely to persist even when health plan leadership changes — the operational stickiness protects Evolent's contracts even through M&A and strategic pivots at the plan level.
Implementation Experience
Health plans implementing the Evolent Performance Suite follow a delegated model that requires careful credentialing and operational handoff. Evolent assumes responsibility for UM functions under the plan's NCQA or URAC accreditation, which means the plan retains regulatory accountability while Evolent operates the clinical review processes. Plans that have managed this transition well have done so by maintaining parallel UM operations during a 90- to 120-day transition window, preserving provider notification workflows, and conducting joint provider education sessions to ensure that specialty practices understand where to submit PA requests under the new structure.
For specialty practices, the implementation experience is often opaque — they learn about the transition when they submit a PA request and receive a response from New Century Health rather than the plan's internal UM team. The most common operational failures at go-live are mis-routed PA submissions (practices using the plan's standard UM portal rather than the New Century Health submission pathway), incorrect fax numbers in provider directories, and benefit structure documents that lag the operational reality by 30 to 60 days. Evolent has acknowledged contact center performance as an operational priority — the company deployed NICE CXone Feedback Management to improve member and provider experience metrics, and implemented Brightmetrics reporting on its Mitel contact center infrastructure to track agent performance and achieve a 95% call answer rate target. These investments reflect real operational scale, but the provider-facing implementation experience in the first 90 days of a new plan contract remains the highest-friction period for billing teams.
When a health plan announces an Evolent or New Century Health delegation in your payer mix, immediately update your prior auth submission pathways and verify fax/portal routing before the effective date — the 90-day transition window is where denial spikes concentrate.
Pricing And Roi Analysis
Evolent's pricing for health plan customers is structured on a per-member-per-month basis, with rates varying by the scope of services delegated and the specialty lines included. Performance Suite engagements that include full oncology and cardiology benefit management carry higher PMPM rates than more limited utilization management-only arrangements. Evolent supplements PMPM base revenue with performance-based fees tied to medical cost trend reduction against benchmarks — this aligns Evolent's financial incentive with demonstrable cost reduction for the plan.
For health plans, the ROI calculation is driven by specialty medical cost trend reduction relative to the PMPM fee. New Century Health's oncology pathway programs have historically demonstrated meaningful reductions in chemotherapy drug cost by steering prescribing toward equivalent-efficacy lower-cost regimens within NCCN guideline bounds. Cardiology programs target high-cost imaging and interventional procedures with evidence-based appropriateness criteria. Whether these trend reductions persist through contract renewal cycles — when Evolent's leverage in renegotiation increases due to switching costs — is a question health plan CFOs should explicitly model.
For specialty practices, there is no direct pricing relationship with Evolent — the financial impact is felt through authorization approval rates, denial rates, and administrative cost of PA submission. Practices operating on National Comprehensive Cancer Network-aligned pathways within New Century Health's program frameworks report smoother prior auth experiences, while practices with high off-pathway utilization face elevated prior auth denial rates and appeals volumes. The administrative cost of managing New Century Health PA workflows on top of standard plan UM processes — particularly in multispecialty practices billing into multiple Evolent-managed payer programs — can be substantial and should be tracked as a discrete cost center in RCM operations.
What To Do Monday Morning
- 1Audit Your Payer Mix for Evolent/New Century Health Delegation
Pull your top 20 payer contracts by volume and identify which ones have delegated specialty benefit management to Evolent's New Century Health subsidiary. Do not rely on your existing payer directory — call each payer's provider relations line directly and ask specifically whether oncology, cardiology, or other specialty benefit programs are managed by a third-party delegated entity. Document the effective date of any delegation, the specific CPT code ranges and specialty lines covered, and the correct PA submission pathway (portal URL, fax number, and clinical criteria source). Update your PA routing protocols before the next claim cycle. This audit should be conducted quarterly, not annually, because delegation arrangements change with health plan contract cycles.
- 2Establish a New Century Health-Specific Denial Tracking Category
Your existing denial tracking almost certainly does not distinguish between denials originating from the health plan's internal UM department and denials originating from New Century Health's specialty benefit management program. That distinction matters because the appeal pathway, the clinical criteria being applied, and the reviewer identity are different for each. Create a denial category in your practice management system specifically for Evolent/New Century Health-sourced denials, tag them by payer, specialty line, and denial reason code, and begin tracking overturn rates on appeal separately. Within 90 days you will have actionable data on whether your appeal process is using the correct pathway — and whether your documentation practices align with New Century Health's clinical criteria rather than generic payer requirements.
- 3Map Your Oncology and Cardiology Coding to New Century Health Pathway Criteria
New Century Health operates NCCN-aligned oncology pathway programs that influence which treatment regimens receive straightforward authorization versus which trigger clinical review. For each of your top 25 chemotherapy or interventional cardiology CPT/HCPCS codes by volume, cross-reference your current treatment documentation practices against the publicly available NCCN guidelines that New Century Health's programs use as a clinical foundation. Where your documentation does not explicitly address pathway alignment — for example, documentation that describes a clinical rationale for an off-pathway regimen without referencing NCCN evidence — update your clinical documentation templates. A coding specificity gap at the documentation level becomes a prior auth denial at the submission level.
- 4Monitor Machinify Integration for Changes in Claims Adjudication Patterns
Evolent's acquisition of Machinify signals that AI-driven claims adjudication is being integrated into its health plan services platform. For any payer where Evolent holds a Performance Suite contract, monitor your first-pass resolution rate and claims adjustment frequency beginning in the second half of 2026. A statistically meaningful drop in first-pass resolution on specialty claims — particularly for high-cost oncology drugs billed under HCPCS J-codes or for cardiology procedures under CPT codes 93454–93461